Symptomatic treatment of seasonal or perennial allergic rhinitis.
Dosage and Administration
General
For therapeutic effectiveness, use at regular intervals.
Administration
Intranasal Administration
Administer by nasal inhalation using a metered-dose nasal spray pump.
Shake inhaler gently immediately prior to use.
Prior to initial use, the metered-dose pump spray must be primed with 5 actuations or until a fine mist appears. Prime pump after a period of nonuse (i.e., > 2 weeks) by actuating once.
Clear nasal passages prior to administration.
Tilt the head slightly forward, insert the spray tip into one nostril, and point the tip toward the back of the nose. Pump the drug into one nostril while holding the other nostril closed and concurrently inspire through the nose. Repeat this procedure for the other nostril.
Dosage
After priming, nasal spray pump delivers about 55 mcg of triamcinolone acetonide per metered spray and about 30 or 120 metered doses per 6.5-g or 16.5-g container, respectively.
Once optimal symptomatic relief is achieved, reduce dosage gradually to the lowest effective level.
Intranasal triamcinolone acetonide should not be continued beyond 3 weeks in the absence of adequate symptomatic improvement.
Pediatric Patients
Seasonal Allergic Rhinitis
Intranasal Inhalation
Children 6–11 years of age: Initially 55 mcg (1 spray) in each nostril once daily (110 mcg total). May be increased to 110 mcg (2 sprays) in each nostril once daily (220 mcg total).
Children ≥12 years of age: 110 mcg (2 sprays) in each nostril once daily (220 mcg total).
Perennial Allergic Rhinitis
Intranasal Inhalation
Children 6–12 years of age: Initially 55 mcg (1 spray) in each nostril once daily (110 mcg total). Maximum, 110 mcg (2 sprays) in each nostril once daily (220 mcg total).
Children ≥12 years of age: Initially 110 mcg (2 sprays) in each nostril once daily (220 mcg total).
Adults
Seasonal Allergic Rhinitis
Intranasal Inhalation
110 mcg (2 sprays) in each nostril once daily (220 mcg total).
Perennial Allergic Rhinitis
Intranasal Inhalation
110 mcg (2 sprays) in each nostril once daily (220 mcg total).
Prescribing Limits
Pediatric Patients
Seasonal or Perennial Allergic Rhinitis
Intranasal Inhalation
Children 6–12 years of age: Maximum 220 mcg (2 sprays in each nostril) daily.
Possible corticosteroid withdrawal symptoms (e.g., joint pain, muscular pain, lassitude, depression), acute adrenal insufficiency, or severe symptomatic exacerbation of asthma or other clinical conditions if prolonged systemic corticosteroid therapy is replaced with topical corticosteroid therapy; careful monitoring recommended.
Use particular caution in patients with associated asthma or other conditions that may be exacerbated by too rapid a reduction in systemic corticosteroid dosage.
Taper the dosage of the systemic corticosteroid, and carefully monitor patients during dosage reduction. In general, the greater the dosage and duration of systemic corticosteroid therapy, the greater the time required for withdrawal of systemic corticosteroids and replacement by intranasal corticosteroids.
Immunosuppressed Patients
Increased susceptibility to infections in patients who are taking immunosuppressant drugs. Certain infections (e.g., varicella [chickenpox], measles) can be serious or fatal in such patients, particularly in children.
Exposure to varicella and measles should be avoided in previously unexposed patients. If exposure to varicella (chickenpox) or measles occurs in susceptible patients, consider administering varicella zoster immune globulin (VZIG) or pooled IM immune globulin (IG) respectively. Consider treatment with antiviral agents if varicella (chickenpox) develops.
Excessive intranasal dosages or use in patients who are particularly sensitive to corticosteroid effects may increase risk of systemic corticosteroid effects (e.g., hypercortism or adrenal suppression). Avoid exceeding the recommended dosages.
Nasopharyngeal Effects
Rarely, localized candidial infections of the nose and/or pharynx has been reported. Local treatment of such infections and/or discontinuance of intranasal therapy may be required.
Category C. Use during pregnancy may result in hypoadrenalism in infants; monitor these infants carefully.
Lactation
Not known whether triamcinolone acetonide is distributed in milk. Caution if used in nursing women.
Pediatric Use
Safety and efficacy not established in children <6 years of age.
Corticosteroids, particularly with high doses for extended periods may cause growth suppression in pediatric patients. Titrate dosage to the lowest possible effective level.
Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as any concomitant illnesses.
Importance of women informing clinicians if they are or plan to become pregnant or to breast-feed.
Importance of advising patients of other important precautionary information. (See Cautions.)
Preparations
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
Triamcinolone Acetonide
Routes
Dosage Forms
Strengths
Brand Names
Manufacturer
Nasal
Suspension
55 mcg/metered spray
Nasacort® AQ Nasal Spray (with benzalkonium chloride)
Remember, keep this and all other medicines out of the reach of children,
never share your medicines with others, and use this medication only for the indication prescribed.
Sign up with Facebook
